US2016326533A1PendingUtilityA1
RNAi-Related Inhibition of TNF-alpha Signaling Pathway for Treatment of Ocular Angiogenesis
Assignee: ARROWHEAD PHARMACEUTICALS INCPriority: Aug 3, 2007Filed: Jul 25, 2016Published: Nov 10, 2016
Est. expiryAug 3, 2027(~1 yrs left)· nominal 20-yr term from priority
A61P 35/00A61P 27/00A61P 27/02C12N 15/1138C12N 15/1137C12N 2310/14C12N 2310/111C12N 15/113C12N 2310/53C12N 2310/141C12N 2310/321C12N 15/1136C12N 2310/531C12N 2310/319C12N 2310/32C12N 2310/31
60
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having a TNFα-related condition or at risk of developing a TNFα-related condition, such as ocular angiogenesis, retinal ischemia, and diabetic retinopathy.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A composition comprising a double-stranded interfering RNA molecule having a length of about 19 to about 49 nucleotides, the interfering RNA molecule comprising:
(a) a sense strand comprising any one of SEQ ID NO:2, SEQ ID NOs:59-154, except that the T's can be T's or U's, and (b) an antisense strand complementary to any one of SEQ ID NO:59-154.
2 . The compositions of claim 1 , wherein each strand of the interfering RNA molecule 19 to about 27 nucleotides in length.
3 . The composition of claim 2 , wherein each strand of the interfering RNA molecule is independently about 19 nucleotides to about 25 nucleotides in length.
4 . The composition of claim 3 , wherein each strand of the interfering RNA molecule is independently about 19 nucleotides to about 21 nucleotides in length.
5 . The composition of claim 1 , wherein the sense and antisense strands are connected by a linker to form a shRNA.
6 . The composition of claim 1 , wherein the interfering RNA molecule has blunt ends.
7 . The composition of claim 1 , wherein at least one strand of the interfering RNA molecule comprises a 3′ overhang.
8 . The composition of claim 7 , wherein the 3′ overhang comprises about 1 to about 6 nucleotides.
9 . The composition of claim 8 , wherein the 3′ overhang comprises 2 nucleotides.
10 . The composition of claim 1 , wherein the interfering RNA molecule comprises at least one modification.
11 . The composition of claim 1 wherein the interfering RNA molecule sense strand and/or antisense strand contains one or more chemically modified nucleotides.
12 . The composition of claim 1 wherein the interfering RNA molecule has at least one blunt end.
13 . The composition of claim 11 wherein the chemically modified nucleotide comprises a ribose 2′-OH modification.
14 . The composition of claim 13 wherein the ribose 2′-OH modification is selected from the group consisting of: 2′-amino group, 2′-O-methyl group, 2′-methoxyethyl group, and 2′-0,4′-C methylene bridge.
15 . The composition of claim 1 the a phosphate group of a sense strand and/or antisense strand nucleotide is modified by substituting one or more of the oxygens of the phosphate group with nitrogen or with sulfur.
16 . The composition of claim 1 , wherein the interfering RNA molecule is a shRNA, a siRNA, or a miRNA.Join the waitlist — get patent alerts
Track US2016326533A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.